• Delhi lose to Bengal by nine wickets in Ranji Trophy opener     • India win Test series against SL 1-0    • India beat Sri Lanka by 165 runs in first Test, take 1-0 lead in series    • First Test at Galle: India dismiss Sri Lanka for 284, take 178-run lead on first innings    • India 460/9 after Day 2 of the first Test against Sri Lanka in Galle    • India thrash Zimbabwe in third and final T20I by 35 runs to clinch series 3-0    • India beat Zimbabwe by seven wickets in the first T20I in Harare    • India lose ODI series against England 2-1 after losing the T20I series 4-0    • India lose T20I series in England 4-0    • India beat Afghanistan 3-0 in ODI series at home    


Health

South Asia’s first skin microbiome test from Leucine Rich Bio sets new standard in personalised skincare

The novel test uses a robust four-stage protocol—beginning with stringent quality control, followed by high-resolution DNA sequencing, proprietary bioinformatics analysis, and multi-level report validation

TDJ News Service

26 Sep, 2025

Leucine Rich Bio Pvt. Ltd., South Asia’s leader in microbiome science, has launched BugSpeaks Skin—the region’s first advanced skin microbiome test designed to revolutionise both skincare and preventive health.

“This distinctive launch marks a critical milestone, delivering science-backed, hyper-personalized skin health insights that go far beyond conventional treatment,” said a statement from the company.

“BugSpeaks Skin stands apart from standard skincare routines by decoding the unique population of beneficial bacteria, fungi, and other microbes residing on the skin.

“These microorganisms are vital for shielding against external threats, regulating immune functions, and maintaining a resilient, youthful skin barrier. Shifts caused by factors such as climate, lifestyle, hormones, or harsh products can undermine this natural balance—often resulting in irritation, breakouts, or sensitivity.”

The novel test uses a robust four-stage protocol—beginning with stringent quality control, followed by high-resolution DNA sequencing, proprietary bioinformatics analysis, and multi-level report validation. Each participant receives a detailed, algorithm-driven report with actionable recommendations for topical formulations, targeted nutrition, and probiotic interventions. Reports are further tailored to account for environmental, dietary, genetic, and lifestyle influences, reflecting the most advanced thinking in “whole-person” skin health.

This launch is propelled by aggressive growth in the global skin microbiome market, estimated at over US$ 1.03 billion in 2024 and projected to triple by 2032. Personalised skin diagnostics, previously accessible to only a select few, are now on the cusp of mainstream adoption. Regions such as the Middle East and GCC, where awareness and wellness spending are rapidly climbing, have been prioritised for expansion.

Dr. Debojyoti Dhar, Co-Founder and Director, comments, “BugSpeaks Skin brings actionable microbiome science straight to daily life. Our goal was to enable individuals to move past generic skincare, giving them precise, data-driven plans for optimal skin health and confidence.”

Kumar Sankaran, CEO of Leucine Rich Bio, adds, “This is a pivotal innovation for the skin healthcare sector. By demystifying the skin microbiome, we’re helping make personalized, effective skincare available to all.”

“Looking ahead, Leucine Rich Bio aims to forge collaborations with dermatologists, wellness providers, and cosmetic leaders to anchor microbiome diagnostics within daily care routines—bridging aesthetics and early risk detection, and setting new standards for preventive healthcare,” the statement said further.

Tags : Skincare, Leucine Rich Bio Pvt. Ltd, microorganisms, skin health